The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis

References

• Pui CH. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia. Front Med. 2015;9:1–9. doi: 10.1007/s11684-015-0381-3
   PubMed Web of Science ®Google Scholar
• Fotoohi AK, Albertioni F. Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leukemia Lymphoma. 2008;49(3):410–426. doi: 10.1080/10428190701824569
   PubMed Web of Science ®Google Scholar
• Pui CH, Campana D, Pei D, et al. Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation. New Engl J Med. 2009;360(26):2730–2741. doi: 10.1056/NEJMoa0900386
   PubMed Web of Science ®Google Scholar
• Relling M V, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12(8):1667. doi: 10.1200/JCO.1994.12.8.1667
   PubMed Web of Science ®Google Scholar
• El-Khodary NM, El-Haggar SM, Eid MA, et al. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol. 2012;29(3):2053–2062. doi: 10.1007/s12032-011-9997-6
   PubMed Web of Science ®Google Scholar
• Wang S M, Sun L L, Zeng W X, et al. Influence of genetic polymorphisms of FPGS, GGH, and MTHFR on serum methotrexate levels in Chinese children with acute lymphoblastic leukemia. Cancer Chem Pharmacology. 2014;74(2):283–289. doi: 10.1007/s00280-014-2507-8
   PubMed Web of Science ®Google Scholar
• Ayad MW, El Naggar AA, El NM. MTHFR c677T polymorphism: association with lymphoid neoplasm and effect on methotrexate therapy. Eur J Haematol. 2014;93(1):63–69. doi: 10.1111/ejh.12302
   PubMed Web of Science ®Google Scholar
• Haase R, Elsner K, Merkel N, et al. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity. Klin Paditr. 2012;224(03):156–159. doi: 10.1055/s-0032-1304623
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Martinguerrero I, Ballesteros J, et al. A systematic review and meta-analysis of MTHFR polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia. Pharmacogenomics J. 2013;13(6):498–506. doi: 10.1038/tpj.2012.44
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008;30(5):347–352. doi: 10.1097/MPH.0b013e318165b25d
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute. 2014 [cited 2018 March 24]. Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605. doi: 10.1007/s10654-010-9491-z
   PubMed Web of Science ®Google Scholar
• Chiusolo P, Reddiconto G, Farina G, et al. MTHFR polymorphisms’ influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leukemia Res. 2007;31(12):1669–1674. doi: 10.1016/j.leukres.2007.03.028
   PubMed Web of Science ®Google Scholar
• Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52(2):166–171. doi: 10.1007/s10038-006-0096-z
   PubMed Web of Science ®Google Scholar
• Ongaro A, De MM, Della Porta MG, et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica. 2009;94(10):1391–1398. doi: 10.3324/haematol.2009.008326
   PubMed Web of Science ®Google Scholar
• Horinouchi M, Yagi M, Imanishi H, et al. Association of genetic polymorphisms with hepatotoxicity in patients with childhood acute lymphoblastic leukemia or lymphoma. Pediatric Hemat Oncol. 2010;27(5):344. doi: 10.3109/08880011003739422
   PubMed Web of Science ®Google Scholar
• Tantawy AA, El-Bostany EA, Adly AA, et al. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrin. 2010;21(1):28–34. doi: 10.1097/MBC.0b013e32833135e9
   PubMed Web of Science ®Google Scholar
• Liu SG, Li ZG, Cui L, et al. Effects of methylenetetrahydrofolate reductase gene polymorphisms on toxicities during consolidation therapy in pediatric acute lymphoblastic leukemia in a Chinese population. Leukemia Lymphoma. 2011;52(6):1030–1040. doi: 10.3109/10428194.2011.563883
   PubMed Web of Science ®Google Scholar
• Karathanasis NV, Stiakaki E, Goulielmos GN, et al. The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia. Genetic Test Mol Bioma. 2011;15(1–2):5. doi: 10.1089/gtmb.2010.0083
   PubMed Web of Science ®Google Scholar
• D'Angelo V, Ramaglia M, Iannotta A, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chem Pharmacol. 2011;68(5):1339–1346. doi: 10.1007/s00280-011-1665-1
   PubMed Web of Science ®Google Scholar
• Sepe DM, Mcwilliams T, Chen J, et al. Germline genetic variation and treatment response on CCG-1891. Pediatric Blood Cancer. 2012;58(5):695–700. doi: 10.1002/pbc.23192
   PubMed Web of Science ®Google Scholar
• Deus DD, Lima ED, Silva RS, et al. Influence of methylenetetrahydrofolate reductase C677T, A1298C, and G80A polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia. Leuk Res Treat. 2012;2012:1–6.
   Google Scholar
• Eissa DS, Ahmed TM. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis. 2013;24(2):181–188.
   PubMed Web of Science ®Google Scholar
• Suthandiram S, Gan GG, Zain SM, et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014;15(11):1479–1494. doi: 10.2217/pgs.14.97
   PubMed Web of Science ®Google Scholar
• Zgheib NK, Akraismail M, Aridi C, et al. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia. Pharmacogenetics Genom. 2014;24(8):387.
   PubMed Web of Science ®Google Scholar
• Roy MN, Kumar A, Agrawal S, et al. Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia. Leukemia Lymphoma. 2015;56(5):1379–1384. doi: 10.3109/10428194.2014.947608
   PubMed Web of Science ®Google Scholar
• Aráoz HV, D'Aloi K, Foncuberta ME, et al. Pharmacogenetic studies in children with acute lymphoblastic leukemia in Argentina. Leukemia Lymphoma. 2015;56(5):1370–1378. doi: 10.3109/10428194.2014.951844
   PubMed Web of Science ®Google Scholar
• Park JA, Shin HY. Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. Blood Res. 2016;51(1):50–57. doi: 10.5045/br.2016.51.1.50
   PubMed Web of Science ®Google Scholar
• Lazic J, Kotur N, Krstovski N, et al. Importance of pharmacogenetic markers in the methylenetetrahydrofolate reductase gene during methotrexate treatment in pediatric patients with acute lymphoblastic leukemia. Arch Biol Sci. 2017;69(2):239–246. doi: 10.2298/ABS160325091L
   Google Scholar
• Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29:551–565. doi: 10.1200/JCO.2010.30.7405
   PubMed Web of Science ®Google Scholar
• Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumour Biol. 2012;33:1445–1454. doi: 10.1007/s13277-012-0395-2
   PubMed Web of Science ®Google Scholar
• Zhao M, Liang L, Ji L, et al. MTHFR gene polymorphisms and methotrexate toxicity in adult patients with hematological malignancies: a meta-analysis. Pharmacogenomics. 2016;17(9):1005–1017. doi: 10.2217/pgs-2016-0004
   PubMed Web of Science ®Google Scholar
• Zhu C, Liu Y W, Wang S Z, et al. Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis. Pharmacogenomics J. 2017;18(3):450–459. doi: 10.1038/tpj.2017.34
   PubMed Web of Science ®Google Scholar